Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colistin + imipenem is an antibiotic combination therapy used for treating multidrug-resistant gram-negative bacterial infections. Colistin (polymyxin E) acts on the bacterial cell membrane, disrupting its integrity and leading to cell death. Imipenem is a carbapenem antibiotic with a wide spectrum of activity against gram-negative and gram-positive aerobic and anaerobic bacteria by inhibiting bacterial cell wall synthesis. This combination has demonstrated synergistic effects against various difficult-to-treat pathogens, including *Enterobacter cloacae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*, particularly in cases where resistance to individual agents has developed. It is primarily used for serious infections like pneumonia, bacteremia, urinary tract infections, and intra-abdominal infections caused by these resistant organisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colistin + imipenem.